Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2026 Jan;32(1):429-431.
doi: 10.3350/cmh.2025.0420. Epub 2025 Apr 28.

Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease"

May Xuan Goh  1 , Xin En Goh  1 , Jarell Jie-Rae Tan  1 , Vincent L Chen  2 , Yu Jun Wong  3   4
Affiliations
Editorial

Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease"

May Xuan Goh et al. Clin Mol Hepatol. 2026 Jan.
No abstract available

Keywords: Korea; Metabolic dysfunction-associated steatohepatitis; Metabolic dysfunction-associated steatotic liver disease; Referral.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

WYJ received funding support from SingHealth Duke-NUS Academic Medical Center (03/FY2020/P2/14-A87) and Changi General Hospital, Singapore (RIG202409-016PI), VLC was supported in part by NIH/NIDDK K08 DK132312.

Comment in

Comment on

References

    1. Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2024;7:101271. - PMC - PubMed
    1. Choo BP, Goh GBB, Chia SY, Oh HC, Tan NC, Tan JYL, et al. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis. Ann Acad Med Singap. 2022;51:686–694. - PubMed
    1. Lee HW, Lee JS, Kim MN, Kim BK, Park JY, Kim DY, et al. Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:1018–1031. - PMC - PubMed
    1. Yip TC, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:304–314. - PubMed
    1. Wong YJ, Urias E, Song MW, Goyal T, Tay WX, Han NX, et al. Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease. Hepatol Commun. 2023;7:e0244. - PMC - PubMed

LinkOut - more resources